CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice

Journal of Surgical Oncology

Volumn 95, Issue 2, 2007, Pages 142-147

  Duraker, Nüvit ^a,b   Hot, Semih ^a   Polat, Yücel ^a   Höbek, Anil ^a   Gençler, Nur ^a   Urhan, Nuray ^a  

^a OKMEYDANI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Ata 2 Sitesi ^*  (Turkey)

Author keywords

Acute pancreatitis; Chronic pancreatitis; Diagnosis; Pancreatic cancer; Tumor marker

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OBSTRUCTIVE JAUNDICE; PANCREAS CARCINOMA; PANCREAS TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNORADIOMETRIC ASSAY; JAUNDICE, OBSTRUCTIVE; PANCREATIC DISEASES; PANCREATIC NEOPLASMS; PANCREATITIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33846918200     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20604     Document Type: Article

References (22)

1. Del Favero G, Fabris C, Plebani M, et al.: CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis. Cancer 1986;57:1576-1579.
2. Haglund C, Roberts PJ, Kuusela P, et al.: Evaluation of CA19-9 as a serum tumor marker in pancreatic cancer. Br J Cancer 1986;53:197-202.
3. Steinberg WM, Gelfand R, Anderson KK, et al.: Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas.Gastroenterology 1986;90:343-349.
4. Pleskow DK, Berger HJ, Gyves J, et al.: Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989;110:704-709.
5. Lucarotti ME, Habib NA, Kelly SB, et al.: Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma. Eur J Surg Oncol 1991;17:51-53.
6. Safi F, Beger HG, Bittner R, et al.: CA 19-9 and pancreatic adenocarcinoma. Cancer 1986;57:779-783.
7. Safi F, Roscher R, Beger HG: Tumor markers in pancreatic cancer: Sensitivity and specificity of CA19-9. Hepatogastroenterology 1989;36:419-423.
8. Ohshio G, Manabe T, Watanabe Y, et al.: Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: Evaluation of the influence of obstructive jaundice. Am J Gastroenterol 1990;85:1370-1376.
9. Röthlin MA, Joller H, Largiader F: CA 242 is a new tumor marker for pancreatic cancer. Cancer 1993;71:701-707.
10. Lurie BB, Loewenstein MS, Zamcheck N: Elevated carcinoembryonic antigen levels and biliary tract obstruction. JAMA 1975;233:326-330.
11. Paganuzzi M, Onetto M, Marroni P, et al.: CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988;61:2100-2108.
12. Mann DV, Edwards R, Ho S, et al.: Elevated tumor marker CA19-9: Clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-479.
13. Haglund C: Tumor marker antigen CA125 in pancreatic cancer: A comparison with CA19-9 and CEA. Br J Cancer 1986;54:897-901.
14. Sakamoto K, Haga Y, Yoshimura R, et al.: Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Gut 1987;28:323-329.
15. Halm U, Rohde N, Klapdor R, et al.: Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease. Anticancer Res 2000;20:4957-4960.
16. Kaiser MH, Barkin JS, Redlhammer D, et al.: Circulating carcinoembryonic antigen in pancreatic carcinoma. Cancer 1978;42:1468-1471.
17. Zamcheck N, Martin EW: Factors controlling the circulating CEA levels in pancreatic cancer: Some clinical correlations. Cancer 1981;47:1620-1627.
18. Uchino R, Kanemitsu K, Obayashi H, et al.: Carcinoembryonic antigen (CEA) and CEA-related substances in the bile of patients with biliary diseases. Am J Surg 1994;167:306-308.
19. Slesak B, Harlozinska-Szmyrka A, Knast W, et al.: Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis: A comparative study with CA 19-9. Cancer 2000;89:83-88.
20. Bergmann J-F, Bidart J-M, George M, et al.: Elevation of CA 125 in patients with benign and malignant ascites. Cancer 1987;59:213-217.
21. Schlieman MG, Ho HS, Bold RJ: Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138:951-956.
22. Safi F, Schlosser W, Kolb G, et al.: Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1997;1:106-112.